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Abstract
Background: Extracting relevant information from microarray data is a very complex
task due to the characteristics of the data sets, as they comprise a large number of
features while few samples are generally available. In this sense, feature selection is a
very important aspect of the analysis helping in the tasks of identifying relevant
genes and also for maximizing predictive information.
Methods: Due to its simplicity and speed, Stepwise Forward Selection (SFS) is a
widely used feature selection technique. In this work, we carry a comparative study
of SFS and Genetic Algorithms (GA) as general frameworks for the analysis of
microarray data with the aim of identifying group of genes with high predictive
capability and biological relevance. Six standard and machine learning-based
techniques (Linear Discriminant Analysis (LDA), Support Vector Machines (SVM), Naive
Bayes (NB), C-MANTEC Constructive Neural Network, K-Nearest Neighbors (kNN) and
Multilayer perceptron (MLP)) are used within both frameworks using six free-public
datasets for the task of predicting cancer outcome.
Results: Better cancer outcome prediction results were obtained using the GA
framework noting that this approach, in comparison to the SFS one, leads to a larger
selection set, uses a large number of comparison between genetic profiles and thus
it is computationally more intensive. Also the GA framework permitted to obtain a
set of genes that can be considered to be more biologically relevant. Regarding the
different classifiers used standard feedforward neural networks (MLP), LDA and SVM
lead to similar and best results, while C-MANTEC and k-NN followed closely but with
a lower accuracy. Further, C-MANTEC, MLP and LDA permitted to obtain a more
limited set of genes in comparison to SVM, NB and kNN, and in particular C-MANTEC
resulted in the most robust classifier in terms of changes in the parameter settings.
Conclusions: This study shows that if prediction accuracy is the objective, the GA-
based approach lead to better results respect to the SFS approach, independently of
the classifier used. Regarding classifiers, even if C-MANTEC did not achieve the best
overall results, the performance was competitive with a very robust behaviour in
terms of the parameters of the algorithm, and thus it can be considered as a
candidate technique for future studies.
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Introduction
DNA microarray technology has been widely used in cancer studies for prediction of
disease outcome [1]. It is a powerful platform successfully used for the analysis of gene
expression in a wide variety of experimental studies [2]. However, due to the large
number of features (in the order of thousands) and the small number of samples
(mostly less than a hundred) in this kind of datasets, microarray data analysis faces the
“large-p-small-n” paradigm [3] also known as the curse of dimensionality. In this
sense, feature selection preprocessing refers to decide which genes to include in the
prediction, and it is a crucial step in developing a class predictor. Including too many
features could reduce the model accuracy and may lead to overfit the data [4]. Two
different algorithms have been widely used in literature to carry out feature selection,
the Stepwise Forward Selection algorithm (SFS) and the Genetic Algorithms (GA). In
the SFS algorithm the choice of predictive features is carried out by an automatic pro-
cedure that starts from single variable models and tests the addition of each feature
using a comparison criterion. This algorithm has been used to identify a predictive
gene signature whose size is minimum [5,6]. GA are also well considered as suitable
evolutionary strategies for feature selection in problems with a large number of fea-
tures [7,8], and are applied to different areas, from object detection [9] to gene selec-
tion in microarray data [10].
On the other hand, model selection is another important step in the estimation of
expression profiles to predict diseases outcome[11]. In this regards, different well-
known machine learning-based techniques have been used recently in literature
wrapped into features selection algorithms to develop a class predictor, e.g. Support
Vector Machines (SVM)[12], Multilayer Perceptron (MLP)[13], k-Nearest Neighbor-
hood (kNN)[14], Linear Discriminant Analysis (LDA)[15] and NaiveBayes. Neverthe-
less, few of these related works brings together different learning algorithms, features
selection schemes and input datasets. Besides, some of them are focused mainly on
optimising the prediction accuracy, and lack of any biological analysis for the resulting
molecular signatures via specialised software as Ingenuity Pathway Analysis (IPA),
GeneOntology (GO) or KEGG [16].
This paper presents an exhaustive analysis of performance for SFS and GA as general
frameworks to estimate expression genes profiles from microarray data with high pre-
dictive capability and biological relevance. Five standard and machine learning-based
techniques (MLP, SVM, kNN, LDA, NaiveBayes) are used within both frameworks
using six free-public cancer datasets (breast, colon, leukemia, lung, ovarian and pros-
tate cancer) for the task of predicting cancer outcome. Moreover, an important goal of
the present study is to test the performance of a new constructive neural network clas-
sification algorithm (C-MANTEC) in the mentioned framework. C-MANTEC have
been previously proved to get similar classification results than traditional multi-layer
perceptrons (MLP) or support vector machines (SVM), with the advantage that the
architecture is dynamically estimated [17]. This is a critical factor in the wrapper selec-
tion methods combined with neural networks, because the subsets analysed are differ-
ent sizes (or even the complexity of the features selected need projections in higher
spaces), which implies that the use of the same architecture is not always appropriate.
On the other hand, considering that using non redundant variables is commonly pre-
ferable in feature selection, the evolutionary strategy presented in this work
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incorporates a mutual information filter to minimise the correlation between the
selected features while increasing the classifier performance. Furthermore, a biological
analysis of the relevance of the selected genes is performed using IPA tool, which can
lead us to conduct an understanding of microarray data.
Methodology
Feature selection techniques can be organised into three broad categories: filter, wrap-
per and embedded methods [18]. Filter methods use statistical properties of the vari-
ables to discard poorly descriptive features and are independent of the classifier.
Wrapper methods are more computationally demanding than filter methods, as subsets
of features are evaluated with a classification algorithm in order to obtain a measure of
goodness to be used as the improvement criteria. Embedded methods are also classifier
dependent, but they can be viewed as a search in the combined space of feature sub-
sets and classifier models, with the additional restriction that it is not possible to
replace the classifier used since feature selection and classification methods work as a
whole.
In this work a comparison between a SFS and GA based approach is done. As the
data input space is quite large for microarray data a pre-selection approach is first
applied in order to reduce the size of the input features to a 5% of the total. After this
reduction, six different classifiers are applied within both frameworks.
Pre-selection step
Since cancer datasets normally contain a large number of genes, a pre-selection step to
reduce the initial number of variables is required. In terms of the quality of the fea-
tures ranked, it has been found that using the Student t-test is generally more success-
ful than other filter methods[19]. In particular, the Welch t-test [20], an adaptation of
the t-test, is used for the pre-selection step assuming the two classes (patient has can-
cer or not) have unknown and unequal variances, as it is not advisable to use the basic
t-test if both requirements are not clearly satisfied [18]. A 5% of the total number of
genes are retained (between 400 and 2000 genes, approximately, in the datasets
selected), which will be the input for the two approaches (SFS and GA) applied, and
described below.
Stepwise forward selection procedure
An exhaustive evaluation of all the possible subsets of n features involves a complexity
of O(2n) which becomes infeasible for large values for n. In this sense, several heuristic
algorithms have been proposed to reduce the computational complexity of wrapper
algorithms. Stepwise forward procedures for feature selection analyse the inclusion of
one or several features in order to improve the performance of the classification task.
Thus, sequential forward selection [21] chooses the best variable in each iteration by
minimising the misclassification rate, and includes it in the final subset of features.
The algorithm will continue to add variables until the performance stops to improve.
Evolutionary approach
GAs are a class of optimisation procedure inspired by the biological mechanisms of
reproduction. One of the key aspects of GA is the so called fitness function f(x), that
should be maximised or minimised over a given space X of arbitrary dimension, in an
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iterative search process in which the population of selected genes evolves as described
in detail below.
Encoding and initial population
A simple encoding scheme to represent as much as possible of the available informa-
tion was employed. A string of bits whose length is equal to the total number of genes
is used, using a binary variable associated with each bit. If the ith bit is active (value 1),
then the ith gene is selected in the chromosome (a value of 0 indicates that the corre-
sponding feature is ignored). Both, the active features and the number of them were
generated randomly, and in all the experiments a population size of 100 individuals
was used.
Selection, crossover and mutation
A selection strategy based on roulette wheel and uniform sampling was applied, while
an elite count value of 10 (number of chromosomes which are retained for the next
generation) was selected. Scattered crossover, in which each bit of the offspring is cho-
sen randomly, was the choice for combining parents of the previous generation, using
a crossover rate set to 0.8. In addition to that, a traditional mutation operator which
flips a specific bit with a probability rate of 0.2 was considered. Since it was empirically
verified that the best subsets include few features, a modification which involves
mutating a random number of bits between 1 and the number of active features of the
individual was also applied, as this change avoids the increment on the number of
active features in the last generations of the GA.
Fitness function
The fitness function assesses each chromosome in the population so that it can be
ranked against all the other chromosomes. Three aspects where considered for con-
structing the fitness function: i) The main objective is to obtain the highest perfor-
mance ii) Among two subsets that achieve equal performance, the one that contains a
lower number of features is preferred. iii) The combination of features with low redun-
dancy among them and with a certain resemblance to the target class, are beneficial for
improving performance rates [22]. Therefore, the fitness function contains three terms:
the misclassification error, the number of features selected and a redundancy measure
among them. Datasets are splitted into training and testing sets in order to evaluate
the generalisation ability of the proposed chromosome.
Statistical techniques such as mutual information [23] can be used for measuring the
correlation between a pair of features. The mutual information between two continu-









where p(y, z) is the joint probability density function of y and z, and p(y) and p(z) are
the marginal probability density functions of y and z respectively.
Mutual information is a non-negative quantity, with a zero value indicating that the
variables are completely independent. The more correlated two variables are, the
greater their mutual information. Advantages of this measure are that the dependency
between variables is no longer restricted to linear correlation and that it can handle
nominal or discrete features. Although it is hard to compute it for continuous data,
the probability densities can be well estimated by discretising it through the use of
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histograms[24]. A measure which incorporates the correlation of features with the tar-













where k is the number of features selected, C is the target class and t is the number of
combinations between the pairs of the chromosome x analysed. Finally, the function to be
minimised ( the f itness(x) function) is represented as follows for a given subset x.
fitness(x) = (1 − ACC(x)) + λ kN + βcorr(x) (3)
where ACC(x) is the accuracy rate obtained by the classifier on the test set (the per-
centage of well-classified patterns with regards to the total patterns analysed); N is
the total number of extracted features; and finally, corr(x) defines the correlation
among the features and the target class, with the aim of avoiding the redundancy in
the feature vector (equation 2). The parameters l and b can take values in the interval
(0, 1) and show how influential are the terms minimisation of the number of genes and
mutual information in the fitness function. Further information is provided in the
results section.
C-MANTEC algorithm
C-MANTEC (Competitive Majority Network Trained by Error Correction) [17] is a
novel neural network constructive algorithm that utilises competition between neurons
and a modified perceptron learning rule to build compact architectures with good pre-
diction capabilities. The novelty of C-MANTEC is that the neurons compete for learn-
ing the new incoming data, and this process permits the creation of very compact
neural architectures. At the single neuronal level, the algorithm uses the thermal per-
ceptron rule, introduced by Marcus Frean in 1992 [25], that improves the convergence
of the standard perceptron for non-linearly separable problems. C-MANTEC, as a
CNN algorithm [26,27], has in addition the advantage of generating online the topol-
ogy of the network by adding new neurons during the training phase, resulting in fas-
ter training times and more compact architectures. Its network topology consists of a
single hidden layer of thermal perceptrons that maps the information to an output
neuron that uses a majority function.
The C-MANTEC algorithm has 3 parameters to be set at the time of starting the
learning procedure. Several experiments have shown that the algorithm is very robust
against changes of the parameter values and thus C-MANTEC operates fairly well in a
wide range of values. The three parameters of the algorithm to be set are: (i) Imax as
maximum number of iterations allowed for each neuron present in the hidden layer
per learning cycle, (ii) gfac a growing factor that determines when to stop a learning
cycle and include a new neuron in the hidden layer, and (iii) Phi () that determines
in which case an input example is considered as noise and removed from the training
dataset according to Eq. 4:
∀X ∈ {X1, ...,XN}, delete(X) |NTL ≥ (μ + ϕσ ) (4)
Luque-Baena et al. Theoretical Biology and Medical Modelling 2014, 11(Suppl 1):S7
http://www.tbiomed.com/content/11/S1/S7
Page 5 of 18
where X represents a given pattern among the N patterns of the dataset, NTL is the
number of times that pattern X has been learnt on the current learning cycle, and the
pair {µ,s} corresponds to the mean and variance of the normal distribution that repre-
sents the number of times that each pattern of the dataset has been learnt during the
learning cycle. Thus, Eq. 4 specifies that if a given pattern (X) has been tried to be
learnt by the network a number of times larger than  standard deviations above the
mean for the population it should be removed from the training set.
Experimental results
In this section, six free-public cancer datasets (http://datam.i2r.a-star.edu.sg/datasets/
krbd/index.html) have been used to test the proposed methodology. The main charac-
teristics (# genes, # samples, and class distribution) for each dataset is shown in Table 1.
A comparison between the two analyzed frameworks is conducted, where for each meth-
odology six classification techniques are applied, namely: LDA, SVM, NaiveBayes,
C-MANTEC, kNN and MLP.
Before applying the methodology based on genetic algorithms, it is necessary to esti-
mate the parameters a and b associated with the fitness function and referred in a pre-
vious section. This estimation is carry out for all the cancer datasets, although only the
information related to the Lung and P rostate datasets are shown by the sake of simpli-
city. Different combinations of the l and b parameters together with the accuracy
results on average and number of selected genes are shown in Table 2. The differences
in the accuracy rates for each parameter combination are not statistically significant,
which implies that, for these cancer datasets, any combination of parameters can be
chosen. Specifically, the combinations a = 0.4, b = 0.25 and a = 0.1, b = 0.25 (Table 2,
in italic), lead to the obtention of the largest success rate, taking into account that
when a is reduced (a = 0.1) the number of genes in the solution is a little higher
(12.78 in P rostate and 4.73 in Lung) than when we try to minimise the solution with
more emphasis (a = 0.4, 9.32 genes in P rostate and 4.25 in Lung, on average).
Table 3 shows the set of parameters that have to be set for each classifier, together
with the different values that have been tested in this paper. For each classifier, a hold-
out validation strategy is used by dividing the entire dataset on a 60 − 40% proportion;
the first set to train the model and the second to obtain the accuracy in the prediction
of cancer outcome. The training-testing procedure is repeated 50 times randomly vary-
ing the training and testing set to avoid a biased evaluation, permitting also to analyse
the dispersion of the results.
A thorough analysis of the parameter setting is presented in Figure 1, where its influ-
ence for the different algorithms is evaluated in the variability of the classification
Table 1 Cancer datasets
Dataset #Genes Samples Class 0 (normal) Class 1 (cancer) Data Proportion
Leukemia 7129 72 25 47 0.347
Lung 12533 181 150 31 0.829
Colon 2000 62 22 40 0.355
Breast 24481 78 33 44 0.423
Ovarian 15154 253 91 162 0.360
Prostate 12600 102 50 52 0.490
Main characteristics of the six cancer datasets analysed.
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accuracy. The horizontal axis corresponds to the average percentage across the 50
samples considered of the false positives (FP) of the data, while the vertical axis is
associated with the false negatives values (FN). Each point of the plot represents the
FP and FN values of a generated configuration with a given parameter setting. The clo-
ser the points are to the origin, the better the classification accuracy, with optimum
performance occurring for FN = FP = 0 (a perfect match between the output of the
algorithm and the observed outcome of the dataset). All points are located always
below the contradiagonal of the plot (FN + FP = 1) as it is verified that FN + FP ≤ 1.
The variability observed for each classifier depends largely on the analysed dataset,
but with the robustness of each of the method having also a strong influence, as more
robust methods yield to more compact configuration clouds of points (a compact con-
figuration cloud means that the results do not vary significantly after a change in the
classifier parameters). Thus, the compactness can be defined as the standard deviation
of the accuracy measures. As shown in Figure 1, the compactness for kNN, SVM and
MLP methods is rather poor in general, while the C-MANTEC approach leads to con-
figurations that are very close together, indicating clearly that the performance of this
method is not very sensitive to the parameter selection. Additionally, C-MANTEC lead
to the lowest values for the distance of the mean of the configuration values (FP and
Table 2 Parameters estimation for GA
Prostate dataset Lung dataset
a b Accuracy #Genes a b Accuracy #Genes
0.8 0.6 0.9838±0.0097 2.67±1.19 0.8 0.6 0.9730±0.0107 8.65±2.82
0.8 0.4 0.9899±0.0072 3.30±1.02 0.8 0.4 0.9748±0.0093 7.28±1.20
0.8 0.25 0.9914±0.0054 3.52±0.91 0.8 0.25 0.9801±0.0106 9.85±3.12
0.4 0.6 0.9827±0.0086 2.56±1.01 0.4 0.6 0.9743±0.0103 8.80±3.18
0.4 0.4 0.9912±0.0069 3.75±1.44 0.4 0.4 0.9763±0.0094 9.55±1.08
0.4 0.25 0.9938 ± 0.0061 4.25 ± 1.95 0.4 0.25 0.9849 ± 0.0089 9.32 ± 1.64
0.1 0.6 0.9837 ± 0.0104 3.04 ± 1.71 0.1 0.6 0.9770 ± 0.0095 7.83 ± 2.06
0.1 0.4 0.9895 ± 0.0065 2.88 ± 0.70 0.1 0.4 0.9763 ± 0.0118 9.63 ± 2.53
0.1 0.25 0.9966 ± 0.0041 4.73 ± 2.10 0.1 0.25 0.9854 ± 0.0101 12.78 ± 1.61
Parameter estimation for the a and b parameters of the fitness function of the GA for the Lung and Prostate datasets.
Table 3 Parameters settings
Algorithm Test Parameters
LDA No parameters
SVM Kernel type, t= {linear, polynomial, radial base function, sigmoid}
Cost, C = {1, 3, 5, 7, 9, 10, 12, 15}
Degree, d = {1, 2, 3, 4, 5}
Gamma, g = {0.001, 0.005, 0.1, 0.15, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 5}
Coef0, r= {0, 1, 2}
NaiveBayes Kernel density, K = {0, 1}
Supervised discretization, D = {0, 1}
C-MANTEC Max. Iterations, Imax = {1000, 10000, 100000}
GFac, gfac = {0.01, 0.05, 0.1, 0.2, 0.25, 0.3}
Phi,  = {1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6}
kNN Neighbours, k = {1, 2, 3, 4, 5, 6, 7, 8, 9, 10}
Distance type, d= {Euclidean, chi-squared, cosine-similarity}
MLP Hidden neurons, N Hidden = {2, 3, 4, 5, 6}
Alpha, a = {0.05, 0.1, 0.2, 0.3, 0.5}
Number cycles, N Cycles = {10, 25, 50}
Parameter settings tested during evaluation of the classification algorithms. The combination of all the values of the
parameters generate a set of configurations for each method.
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FN) to the origin, confirming the robustness in the parameter setting (the LDA classi-
fier does not have parameters to be set and thus it is not represented in the graph). In
order to quantify the distribution of the prediction accuracy observed for the several
configuration analysed, the legend for each classifier shows the distance to the plot ori-
gin plus/minus the standard deviation
(√
(FP)2 + (FN)2 ± std-dev
)
. For example, for
the Ovarian, Colon and Prostate datasets, the distance to the origin for the mean value
observed for the C-MANTEC algorithm is significantly lower than for the rest of alter-
natives (0.0109, 0.102 and 0.0602, respectively).
Figure 1 Quantitative measures. False Positives (FP) and False Negatives (FN) ratios after applying each
method to the test sequences with all the parameter configurations. Each coloured point ‘*’ is considered
as a different configuration for the indicated method. The closer the points are to the origin, the better the
segmentation. Additionally, the method is less sensible to a parameters’ change if the cloud of points is
more compact (see the text for more details). The datasets are different and so the scales are.
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Comparison results between the two frameworks are shown in Table 4, where the best
parameter configuration for each classification model is selected to perform the evalua-
tion over the six datasets. In both frameworks, the accuracy rates for the Leukemia,
Lung and Ovarian datasets are close to 100% regardless of the classifier applied, suggest-
ing a low data complexity (in prediction terms). The complexity the Breast, Colon and
Prostate seems higher, permitting to observe clear differences between the two
approaches. The prediction accuracy obtained with the GA methodology was in almost
all cases higher that the obtained within the SFS approach. Additionally, the robustness
of the selected features is considerably higher in the GA (lower standard deviation
Table 4 Performance comparison of classification techniques
GA SFS
Classifier Parameters mean ± std #genes mean ± std #genes
Leukemia LDA - 99.959 ± 0.07 12 97.609 ± 2.86 2
SVM {polynomial,15,1,0.6,0} 99.982 ± 0.06 8 99.918 ± 0.52 4
NaiveBayes {1,0} 99.974 ± 0.03 12 98.060 ± 2.19 3
C-MANTEC {1000,0.01,4.5} 99.038 ± 0.25 7 98.837 ± 2.46 3
kNN {1,Euclidean} 99.994 ± 0.02 10 99.844 ± 0.77 5
MLP {3,0.5,50} 99.944 ± 0.05 5 95.784 ± 3.38 2
Lung LDA - 99.971 ± 0.03 5 99.057 ± 1.00 3
SVM {linear,10,-,-,-} 100 ± 0 11 99.828 ± 0.70 3
NaiveBayes {1,0} 99.998 ± 0.01 4 99.991 ± 0.07 3
C-MANTEC {100000,0.25,2} 99.678 ± 0.08 6 99.673 ± 0.94 2
kNN {1,Euclidean} 99.969 ± 0.02 4 99.969 ± 0.22 4
MLP {4,0.1,50} 99.996 ± 0.01 4 99.778 ± 0.79 2
Colon LDA - 98.676 ± 0.35 11 87.179 ± 6.15 2
SVM {polynomial,1,1,0.4,2} 89.917 ± 1.26 20 91.738 ± 5.21 5
NaiveBayes {0,1} 90.583 ± 0.49 15 89.076 ± 7.79 4
C-MANTEC {10000,0.01,1} 94.315 ± 0.48 11 87.593 ± 6.69 2
kNN {3,cosine-similarity} 95.060 ± 0.38 19 93.577 ± 4.43 6
MLP {5,0.3,50} 99.026 ± 0.30 12 88.733 ± 5.51 2
Breast LDA - 99.788 ± 0.12 15 74.169 ± 6.52 1
SVM {polynomial,7,2,0.001,2} 99.744 ± 0.14 31 81.029 ± 5.80 3
NaiveBayes {0,0} 97.759 ± 0.23 27 73.499 ± 6.34 1
C-MANTEC {10000,0.01,1.5} 97.342 ± 0.39 23 76.645 ± 6.53 1
kNN {3,Euclidean} 97.485 ± 0.30 34 80.975 ± 6.37 2
MLP {4,0.3,50} 99.828 ± 0.09 18 79.191 ± 6.43 2
Ovarian LDA - 99.980 ± 0.01 4 100 ± 0 3
SVM {polynomial,9,1,0.2,0} 100 ± 0 4 99.978 ± 0.13 4
NaiveBayes {1,0} 99.951 ± 0.03 5 99.980 ± 0.13 4
C-MANTEC {1000,0.3,1.5} 99.844 ± 0.05 4 99.659 ± 0.75 3
kNN {1,Euclidean} 99.984 ± 0.01 4 99.982 ± 0.11 3
MLP {5,0.3,50} 99.999 ± 0 3 100 ± 0 3
Prostate LDA - 99.720 ± 0.12 9 95.677 ± 2.81 4
SVM {polynomial,5,1,3,1} 99.428 ± 0.31 20 98.622 ± 1.79 5
NaiveBayes {0,0} 98.817 ± 0.16 14 98.331 ± 2.13 7
C-MANTEC {1000,0.25,4} 98.681 ± 0.24 8 95.351 ± 3.40 4
kNN {3,cosine-similarity} 99.633 ± 0.11 20 97.146 ± 2.28 6
MLP {3,0.5,50} 99.996 ± 0.02 12 96.921 ± 2.37 4
Performance comparison among the two different feature selection frameworks used (GA and SFS) and the six classifiers
analyzed (LDA, SVM, NaiveBayes, C-MANTEC, kNN and MLP) for each cancer microarray dataset. The results correspond
to the best simulation for each dataset, showing the accuracy for method in the format of mean ± standard deviation
and the number of selected genes.
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values), fact that can be partially attributed to the larger set of genes selected. Regarding
the computational complexity of both approaches, the SFS strategy involves approxi-
mately a number of comparisons of nsel × #genes (nsel: number of pre-selected features,
#genes : mean number of genes selected), while the GA approach utilises a maximum of
20.000 profile comparisons regardless of the dataset (length of the chromosome (100) ×
number of generations (200)). For example, for the Prostate dataset in the SFS approach,
approximately 3000 comparison are needed in the present study since nsel ≈ 600,
#genes = 5 , unlike the genetic proposal which requires a greater number of combina-
tions. However, if the number of pre-selected genes increases, the SFS method begins to
loose its efficiency and may be intractable when handling thousands of genes.
Table 5 shows average results across all six datasets for the both frameworks used,
noting that C-MANTEC lead to competitive classification performance with a reduced
number of genes.
Further, we analyzed the differences between classifiers for the SFS and GA feature
selection procedures used and for the six datasets, showing the results in Table 6. The
corresponding p-value obtained after applying a Friedman’s test is indicated in the
third column [28]. In case this p-value is lower than 0.05, the lowest performant classi-
fier is taken as a control group and the last column of the table lists the classifiers that
lead to statistically significant results (from the lowest to the highest difference);
Table 5 Performance comparison of feature selection frameworks
GA SFS
Classifier mean ± std #genes mean ± std #genes
LDA 99.682 ± 0.12 9.33 92.282 ± 3.22 2.5
SVM 99.082 ± 0.25 15.67 95.185 ± 2.36 4
NaiveBayes 97.847 ± 0.16 12.83 93.156 ± 3.11 3.67
C-MANTEC 98.150 ± 0.25 9.83 92.960 ± 3.46 2.5
kNN 98.688 ± 0.14 15.17 95.249 ± 2.36 4.33
MLP 99.798 ± 0.08 9 93.401 ± 3.08 2.5
Average performance comparison among two different feature selection frameworks (GA and SFS) and six classifiers
(LDA, SVM, NaiveBayes, C-MANTEC, kNN and MLP) over all dataset.
Table 6 Differences between classifiers.
FS procedure Dataset p-value Control Statistically different classifiers
SFS Leukemia < e−16 LDA SVM
Lung < e−16 LDA kNN, NB
Colon < e−16 LDA SVM, kNN
Breast < e−16 NB kNN, SVM
Ovarian < e−16 CM LDA, NN
Prostate < e−16 CM NB, SVM
GA Leukemia < e−16 CM NB, NN, LDA, SVM, kNN
Lung < e−16 CM SVM, NB, NN
Colon < e−16 SVM LDA, NN
Breast < e−16 SVM NN, LDA
Ovarian < e−16 CM SVM, NN
Prostate < e−16 CM NN, LDA
Differences between classifiers for the two feature selection (FS) procedures used (first column). The lowest performance
classifier is taken as control group and the last column of the table lists the classifiers that lead to statistically significant
results (corresponding p-value indicated in the third column).
Luque-Baena et al. Theoretical Biology and Medical Modelling 2014, 11(Suppl 1):S7
http://www.tbiomed.com/content/11/S1/S7
Page 10 of 18
otherwise, non statistically significant results are reached (represented with a “-” on the
table).
Table 7 shows a similar comparative analysis but among the SFS and GA feature
selection procedures when a common classifier is used (first column of the table).
Biological analysis
Figures 2 and 3 present the ten most selected genes for each of the six datasets consid-
ered, where each dataset is represented in a row of the table. The first three columns
show information about the gene, such as the internal index (ID), the gene symbol
(name of the gene) and the probe set ID, which is related to the chip where the dataset
Table 7 Differences between feature selection algorithms
Classifier Dataset p-value Control Statistically different FS procedures
LDA Leukemia 1.54e−12 SFS GA
Lung 1.54e−12 SFS GA
Colon 1.54e−12 SFS GA
Breast 1.54e−12 SFS GA
Ovarian 3.28e−11 GA SFS
Prostate 1.54e−12 SFS GA
SVM Leukemia 3.65e−5 SFS GA
Lung 1.54e−12 SFS GA
Colon 2.86e−9 GA SFS
Breast 1.54e−12 SFS GA
Ovarian 9.13e−11 SFS GA
Prostate 1.54e−12 SFS GA
NB Leukemia 4.71e−9 SFS GA
Lung 1.54e−12 SFS GA
Colon 1.54e−12 SFS GA
Breast 1.54e−12 SFS GA
Ovarian 0.157 - -
Prostate 1.54e−12 SFS GA
CM Leukemia 4.71e−9 SFS GA
Lung 1.54e−12 SFS GA
Colon 1.54e−12 SFS GA
Breast 1.54e−12 SFS GA
Ovarian 0.157 - -
Prostate 1.54e−12 SFS GA
kNN Leukemia 1.54e−12 SFS GA
Lung 0.0897 - -
Colon 1.54e−12 SFS GA
Breast 1.54e−12 SFS GA
Ovarian 0.6547 - -
Prostate 1.54e−12 SFS GA
NN Leukemia 4.71e−9 SFS GA
Lung 1.54e−12 SFS GA
Colon 1.54e−12 SFS GA
Breast 1.54e−12 SFS GA
Ovarian 0.157 - -
Prostate 1.54e−12 SFS GA
Differences between SFS and GA feature selection algorithms for the six different classification methods used (first
column). The lowest performant FS procedure is taken as control group (fourth column) while the last column of the
table lists the procedures that lead to statistically significant results (corresponding p-value indicated in the third
column)
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has been extracted (e.g., Affymetrix). The bar graph of the last column splits the fre-
quency of selection (fourth column) of each feature according to the GA-LDA, GA-
SVM, GA-CMANTEC, GA-kNN, GA-NaiveBayes and GA-MLP strategies. Most of the
gene symbols have been found from their probe set ID by using tools as IPA (Ingenuity®
Figure 2 Frequency selection of genes for Leukemia, Lung, Colon and Breast databases. The ten
most selected features for the analysed datasets. Frequency selection is represented by an horizontal bar,
divided according to the six classifiers used in the analysis: LDA, SVM, C-MANTEC, kNN, NaiveBayes and
MLP. The index, gene symbol and probe set ID of each gene is shown in columns one to three.
Figure 3 Frequency selection of genes for Ovarian and Prostate databases. The ten most selected
features for the analysed datasets. The structure of this figure is the same than Figure 2.
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Systems, http://www.ingenuity.com) or NCBI (http://www.ncbi.nlm.nih.gov/gene/),
although it has not been possible for the Ovarian dataset (first row of Figure 3) because
there is no reference of the chip from which the data have been extracted.
A higher frequency of selection might imply a higher relevance of the gene in the
prognosis of the disease. Those genes that are selected with similar frequency for all
classifiers are considered independent with respect to the classification method. For
instance, in the Prostate dataset (second row of Figure 3), the MAF gene is more sig-
nificant than the JUNB gene, since it has been selected more times and all the classi-
fiers selects it with the same frequency. Thus, NaiveBayes barely takes into account
the JUNB gene whereas for MLP classifier it is one of the main genes.
Not only are we interested in getting good results in prognosis prediction but also in
examining whether the selected genes provide biological information related to the dis-
ease studied. Therefore, if the proposed models provide this consistency between the
computational and biological field, the results would be more confident and the
selected genes would be more reliable from a clinical perspective, in order to their
implementation in microchips and treatment in real patients. We can see that this
statement is true in the proposed model using genetic algorithms.
In the case of the Prostate dataset is possible to find references in the literature where
the genes MAF, which encodes a protein related to DNA-binding (most frequent gene,
99.67%) [29], SERPINB5, a serpin peptidase inhibitor (second most frequent, 58%) [30],
HPN, officially named hepsin which encodes a type II transmembrane serine protease
(fourth most frequent, 50%) [31] and GSTP1, belonging to the family of Glutathione
S-transferases (GSTs) enzymes (sixth most frequent, 36.33%) [32] are biologically related
to the absence or presence of prostate cancer. This supports the idea that our computa-
tional approach is robust and consistent with the results obtained in biological studies.
For the Breast dataset, several of the most selected genes among which are UBC
[33,34], ZNF222 [35] and EWSR1 [36], are biologically associated with breast cancer.
The same happen for the Leukemia disease, where the enforced expression of the
CD19 molecule (fifth selected, 19%) can reduce the proliferation of the malignant
plasma cells [37]; the gene homeobox A9 (HOXA9, second selected, 33%) influences
hematopoietic progenitors and acute leukemias [38]; and the CD33 molecule (seventh
selected, 17.33%) has been shown to sharply inhibit the in vitro proliferation of both
normal myeloid cells and chronic myeloid leukemias [39].
From a computational point of view, Table 8 shows the best selected genes obtained
by the genetic approach which also have been extracted in several related papers (last
column of the table) for the particular case of the Leukemia dataset. It should be
noted that the applied methodology is different from one paper to another. For
instance, five of the ten genes are also reported in the list of the 50 most important
genes (selected from 7129) suggested in [40].
Focusing on the Leukemia dataset (one of the most studied dataset in the litera-
ture), and as a biological analysis of the features selected, Figure 4 displays a com-
parison between the most selected genes, after 50 independent executions and with
independence of the classifier used, for both GA and SFS selection procedures.
Moreover, the IPA tool is used in order to explore the functional involvement of
each gene set obtained by GA and SFS in the studied disease. In concrete, three of
the fifteen most frequently genes are highlighted in bold on the x-axis in Figure 4 as
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founded genes in the IPA database with biological relevance on the Leukemia cancer
disease.
A deeper biological analysis is performed using the IPA tool for the GA-CMANTEC
strategy considering the Leukemia dataset. Figure 5 shows those genes that are selected
at least a 5% of the times both with GA-CMANTEC or SFS-CMANTEC strategy after
50 independent executions. The names shown on this figure correspond to the symbol
of each gene according to Figure 2. It is important to highlight the difference on the
number of genes selected through the GA and SFS strategy due to the casuistic of
each algorithm. Additionally, on the left side are represented in bold nine of the ten
most frequently selected genes with independence of the classifier used. Moreover,
using C-MANTEC as classifier allow to obtain these nine most selected genes. Finally,
filled in genes represent those genes that have demonstrate biological relevance on the
Leukemia disease. In this sense, the GA-CMANTEC strategy presents 10 out of 37
genes as a result while the SFS-CMANTEC strategy presents 2 out of 7. Although
these results are similar in proportion, the GA-CMANTEC strategy could be consid-
ered more explicative from a biological point view with no detriment on the classifica-
tion performance. Furthermore, the connections among the selected genes
(represented by links in Figure 5), which are more numerous in the GA approach, sug-
gest as well a significant relationship with the occurrence of the disease.
Conclusions
In this work, a new methodology approach combining genetic algorithm with con-
structive neural networks has been proposed in order to predict cancer outcome. For
six free-public cancer datasets, we compared under GA and SFS frameworks the pre-
diction accuracy of the C-MANTEC algorithm against the following five standard clas-
sifiers: LDA, SVM, NaiveBayes, kNN or MLP.
On average, the strategy based on the GA approach leads to better prediction rates,
observing that these results are independent of the classifier used, noting also that pre-
diction results under the GA framework show lower variability, and thus can be con-
sidered as more robust. On the other hand, it should be noted that the SFS approach
is less computationally intensive, involving in the present study approximately seven
times less gene comparisons, and also leading to a group of selected genes much smal-
ler than those selected under the GA approach. Nevertheless, when complex datasets
Table 8 Selected genes for the Leukemia dataset
ID Probe Set ID Gene Description References
4951 Y07604_at NME/NM23 nucleoside diphosphate kinase 4 [41-43]
3847 U82759_at Homeo box A9 [40,44,43]
6169 M13690_s_at C1NH Complement component 1 inhibitor [43,45]
6184 M26708_s_at PTMA Prothymosin alpha [45]
6225 M84371_rna1_s_at CD19 Molecule [46]
1882 M27891_at CST3 Cystatin C [40,41,43,44]
1834 M23197_at CD33 antigen [40,44,46]
4847 X95735_at Zyxin [40,41,44,46]
3320 U50136_rna1_at LTC4 synthase [40,43,44,46]
5094 Z24727_at TPM1 Tropomyosin alpha chain [47]
The best selected genes ranked with the GA approach for the Leukemia dataset which also appear in other studies in
the literature.
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are studied like Breast or Colon, cancer prognosis results are quite poor when using
the SFS approach, presumably since the search in the state space is much more restric-
tive. Additionally, an analysis done using the IPA methodology suggests that the biolo-
gical relevance of the genes selected under the GA framework is higher than the
observed using the SFS approach, as indicated by the reference frequency in the litera-
ture and also regarding the relationship between them (even if this effect might be due
to the size of both selected sets).
Figure 4 Comparison of the most frequently selected genes. Comparison of the most frequently
selected genes (in 50 independent executions) by the GA and SFS strategy in Leukemia dataset, with
independence of the classifier used.
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Regarding the comparison between the different classifiers implemented, standard feed-
forward neural networks (MLP), LDA and SVM lead to similar and best results while
C-MANTEC and kNN followed closely but with a bit lower accuracy. C-MANTEC, MLP
and LDA permitted to obtain a more reduced set of genes in comparison to SVM, NB and
kNN. Further, C-MANTEC resulted in the most robust classifier in terms of changes in
the parameter settings, a relevant feature for its use in wrapper feature selection methods
(as it will reduce execution times related to parameter tuning). Additionally, we are con-
sidering the use of a ensemble of all these classifiers as a further work, in order to obtain a
greater consensus on the classification result, which could lead to greater robustness and
accuracy of the resulting model.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RML, DU and JMJ contributed to the conception and design of the study. RML, DU and JLS contributed to write the
programming code. RML, DU, JMJ and LF contributed to the analysis and interpretation of the data, and RML, DU, LF
and JMJ contributed to the drafting of the manuscript. All authors approved the manuscript.
Declarations
Publication funding for this article has come from grants TIN2010-16556 (MICINN-Spain) and TIC-4026/2008 (Consejería
de Innovación, Ciencia y Empresa. Junta de Andalucía), both including FEDER funds. Additionally, the authors
acknowledge support through these grants.
This article has been published as part of Theoretical Biology and Medical Modelling Volume 11 Supplement 1, 2014:
Selected articles from the 1st International Work-Conference on Bioinformatics and Biomedical Engineering-IWBBIO
2013. The full contents of the supplement are available online at http://www.tbiomed.com/supplements/11/S1.
Authors’ details
1Department of Computer Science, University of Málaga, Málaga, Spain. 2Biomedical Research Institute of Málaga
(IBIMA), Spain.
Figure 5 Biological analysis for Leukemia dataset. Biological analysis of the resuls obtained by GA-
CMANTEC and SFS-CMANTEC strategy for the Leukemia dataset using the IPA tool.
Luque-Baena et al. Theoretical Biology and Medical Modelling 2014, 11(Suppl 1):S7
http://www.tbiomed.com/content/11/S1/S7
Page 16 of 18
Published: 7 May 2014
References
1. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG: Prediction of Clinical Outcome Using Gene Ex-pression
Profiling and Artificial Neural Networks for Patients with Neuroblastom. Cancer Research 2004, 64:6883-6891.
2. Pellagatti A, Vetrie D, Langford CF, Gama S, Eagleton H, Wainscoat JS, Boultwood J: Gene Expression Profiling in
Polycythemia Vera Using cDNA Microarray Technology. Cancer Research 2003, 63:3940-3944.
3. West M: Bayesian factor regression models in the “large p, small n” paradigm. Bayesian statistics 2003,
7(2003):723-732.
4. Ransohoff D: Rules of evidence for cancer molecular-marker discovery and validation. Nature Reviews Cancer 2004,
4(4):309-314.
5. Lancashire LJ, Rees RC, Ball GR: Identification of gene transcript signatures predictive for estrogen receptor and
lymph node status using a stepwise forward selection artificial neural network modelling approach. Artificial
Intelligence In Medicine 2008, 43(2):99-111.
6. Peng H, Fu Y, Liu J, Fang X, Jiang C: Optimal gene subset selection using the modified SFFS algorithm for tumor
classification. Neural Computing and Applications 2012, 1-8.
7. Raymer M, Punch W, Goodman E, Kuhn L, Jain A: Dimensionality reduction using genetic algorithms. IEEE
Transactions on Evolutionary Computation 2000, 4(2):164-171.
8. Chiang Y, Chiang H, Lin S: The application of ant colony optimization for gene selection in microarray-based cancer
classification. Proceedings of the 7th International Conference on Machine Learning and Cybernetics, ICMLC 2008,
7:4001-4006.
9. Sun Z, Bebis G, Miller R: Object detection using feature subset selection. Pattern Recognition 2004, 37(11):2165-2176.
10. McLachlan G, Bean R, Peel D: A mixture model-based approach to the clustering of microarray expression data.
Bioinformatics 2002, 18(3):413-422.
11. Molinaro A, Simon R, Pfeiffer R: Prediction error estimation: a comparison of resampling methods. Bioinformatics
2005, 21(15):3301-3307.
12. Zhang F, Kaufman HL, Deng Y, Drabier R: Recursive SVM biomarker selection for early detection of breast cancer in
peripheral blood. BMC Medical Genomics 2013, 6(1).
13. Tong DL, Schierz AC: Hybrid genetic algorithm-neural network: Feature extraction for unpreprocessed microarray
data. Artificial Intelligence in Medicine 2011, 53:47-56.
14. Su Y, Wang R, Li C, Chen P: A dynamic subspace learning method for tumor classification using microarray gene
expression data. Proceedings - 2011 7th International Conference on Natural Computation, ICNC 2011 2011, 1:396-400.
15. Student S, Fujarewicz K: Stable feature selection and classification algorithms for multiclass microarray data. Biology
Direct 2012, 7.
16. Werner T: Bioinformatics applications for pathway analysis of microarray data. Current Opinion in Biotechnology 2008,
19:50-54.
17. Subirats JL, Franco L, Jerez JM: C-Mantec: A novel constructive neural network algorithm incorporating competition
between neurons. Neural Networks 2012, 26:130-140.
18. Saeys Y, Inza I, Larranãga P: A review of feature selection techniques in bioinformatics. Bioinformatics 2007,
23(19):2507-2517.
19. Huerta EB, Duval B, Hao JK: A hybrid LDA and genetic algorithm for gene selection and classification of microarray
data. Neurocomputing 2010, 73:2375-2383.
20. Welch BL: The generalization of Student´s problem when several different population variances are involved.
Biometrika 1947, 34(1-2):28-35.
21. Webb AR: Statistical Pattern Recognition. 2 edition. John Wiley & Sons; 2011, third edition.
22. Peng H, Long F, Ding C: Feature selection based on mutual information criteria of max-dependency, max-
relevance, and min-redundancy. IEEE Transactions on Pattern Analysis and Machine Intelligence 2005, 27(8):1226-1238.
23. Guo B, Nixon M: Gait Feature Subset Selection by Mutual Information. IEEE Transactions on Systems, Man and
Cybernetics, Part A: Systems and Humans 2009, 39:36-46.
24. Moddemeijer R: On Estimation of Entropy and Mutual Information of Continuous Distributions. Signal Processing
1989, 16(3):233-246.
25. Frean M: A “thermal” perceptron learning rule. Neural Comput. 1992, 4(6):946-957.
26. García-Pedrajas N, Ortiz-Boyer D: A cooperative constructive method for neural networks for pattern recognition.
Pattern Recogn. 2007, 40:80-98.
27. Subirats JL, Jerez JM, Franco L: A New Decomposition Algorithm for Threshold Synthesis and Generalization of
Boolean Functions. IEEE Transactions on Circuits and Systems 2008, 1(55):3188-3196.
28. García S, Fernández A, Luengo J, Herrera F: Advanced nonparametric tests for multiple comparisons in the design of
experiments in computational intelligence and data mining: Experimental analysis of power. Information Sciences
2010, 180(10):2044-2064.
29. Steele VE, Arnold JT, Le H, Izmirlian G, Blackman MR: Comparative Effects of DHEA and DHT on Gene Expression in
Human LNCaP Prostate Cancer Cells. Anticancer Research 2006, 26(5A):3205-3215.
30. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R: Maspin acts at the cell membrane to inhibit invasion and
motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA 1996, 93(21):11669-74.
31. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S: HEPSIN Inhibits Cell Growth/Invasion in Prostate Cancer
Cells. Cancer Research 2002, 62(23):6812-6816.
32. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, van Rees B, Gage WR, Bova GS, Isaacs WB,
Brooks JD, DeWeese TL, Marzo AMD, Nelson WG: {GSTP1} CpG Island Hypermethylation Is Responsible for the
Absence of {GSTP1} Expression in Human Prostate Cancer Cells. The American Journal of Pathology 2001,
159(5):1815-1826.
Luque-Baena et al. Theoretical Biology and Medical Modelling 2014, 11(Suppl 1):S7
http://www.tbiomed.com/content/11/S1/S7
Page 17 of 18
33. Ramachandran C, Rodriguez S, Ramachandran R, Nair PR, Fonseca H, Khatib Z, Escalon E, Melnick SJ: Expression Profiles
of Apoptotic Genes Induced by Curcumin in Human Breast Cancer and Mammary Epithelial Cell Lines. Anticancer
Research 2005, 25(5):3293-3302.
34. Kroll T, Odyvanova L, Clement J, Platzer C, Naumann A, Marr N, Höffken K, Wölfl S: Molecular characterization of
breast cancer cell lines by expression profiling. Journal of Cancer Research and Clinical Oncology 2002, 128(3):125-134.
35. Klein A, Olendrowitz C, Schmutzler R, Hampl J, Schlag PM, Maass N, Arnold N, Wessel R, Ramser J, Meindl A,
Scherneck S, Seitz S: Identification of brain-and bone-specific breast cancer metastasis genes. Cancer Letters 2009,
276(2):212-220.
36. Menon R, Omenn GS: Proteomic Characterization of Novel Alternative Splice Variant Proteins in Human Epidermal
Growth Factor Receptor 2 neu Induced Breast Cancers. Cancer Research 2010, 70(9):3440-3449.
37. Mahmoud MS, Fujii R, Ishikawa H, Kawano MM: Enforced CD19 Expression Leads to Growth Inhibition and Reduced
Tumorigenicity. Blood 1999, 94(10):3551-3558.
38. Hu YL, Fong S, Ferrell C, Largman C, Shen WF: HOXA9 Modulates Its Oncogenic Partner Meis1 To Influence Normal
Hematopoiesis. Molecular and Cellular Biology 2009, 29(18):5181-5192.
39. Vitale C, Romagnani C, Puccetti A, Olive D, Costello R, Chiossone L, Pitto A, Bacigalupo A, Moretta L, Mingari MC:
Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: Engagement of CD33
induces apoptosis of leukemic cells. Proceedings of the National Academy of Sciences 2001, 98(10):5764-5769.
40. Golub T, Slonim D, Tamayo P, Huard C, Gaasenbeek M, Mesirov J, Coller H, Loh M, Downing J, Caligiuri M, Bloomfield C,
Lander E: Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring.
Science 1999, 286(5439):531-537.
41. Yang P, Zhou BB, Zhang Z, Zomaya AY: A multi-filter enhanced genetic ensemble system for gene selection and
sample classification of microarray data. BMC Bioinformatics 2010, 11(1).
42. García-Nieto J, Alba E, Jourdan L, Talbi E: Sensitivity and specificity based multiobjective approach for feature
selection: Application to cancer diagnosis. Information Processing Letters 2009, 109(16):887-896.
43. Krishnapuram B, Carin L, Hartemink A: Joint classifier and feature optimization for comprehensive cancer diagnosis
using gene expression data. Journal of Computational Biology 2004, 11(2-3):227-242.
44. Chen Z, Li J, Wei L: A multiple kernel support vector machine scheme for feature selection and rule extraction
from gene expression data of cancer tissue. Artificial Intelligence in Medicine 2007, 41(2):161-175.
45. Shen Q, Shi WM, Kong W: Hybrid particle swarm optimization and tabu search approach for selecting genes for
tumor classification using gene expression data. Computational Biology and Chemistry 2008, 32:53-60.
46. Momin B, Mitra S, Gupta R: Reduct Generation and Classification of Gene Expression Data. Hybrid Information
Technology, 2006 ICHIT ‘06 International Conference on 2006, 1:699-708.
47. Gwinn M, Keshava C, Olivero O, Humsi J, Poirier M, Weston A: Transcriptional signatures of normal human mammary
epithelial cells in response to benzo[a]pyrene exposure: a comparison of three microarray platforms. OMICS 2005,
9(4):334-50.
doi:10.1186/1742-4682-11-S1-S7
Cite this article as: Luque-Baena et al.: Application of genetic algorithms and constructive neural networks for
the analysis of microarray cancer data. Theoretical Biology and Medical Modelling 2014 11(Suppl 1):S7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Luque-Baena et al. Theoretical Biology and Medical Modelling 2014, 11(Suppl 1):S7
http://www.tbiomed.com/content/11/S1/S7
Page 18 of 18
